4th Jun 2019 10:08
LONDON (Alliance News) - Renalytix AI PLC said high quality production-scale batches of the materials needed for its KidneyIntelX test have now been produced.
Shares in Renalytix AI, which is focused on developing clinical tests for kidney disease, were up 5.9% at 214.00 pence in morning trade.
KidneyIntelX is a diagnostic test which uses a combination of predictive blood-based biomarkers and machine learning algorithms, as well as the patient's electronic health record, to find people who with a high likelihood of fast-progressing kidney disease.
The materials are necessary for the measuring of predictive blood-based biomarkers, substances in the blood which are associated with more rapid kidney disease progression.
The company said multiple production-scale lots of critical materials needed for the test were made. This is a key milestone in the scaling up of manufacturing for commercial production.
The materials met quality control specifications and are the result of a collaboration with Meso Scale Diagnostics LLC, which is manufacturing the materials for KidneyIntelX.
Renalytix AI Chief Technology Officer Fergus Fleming said: "Working closely with MSD, we have successfully demonstrated that the KidneyIntelX biomarkers sTNFR1, sTNFR2 and KIM-1 can be accurately measured using components manufactured in a highly automated, quality-controlled production facility. As a result, we have now secured our supply of biomarker assay components required to support scaled commercial testing."
Related Shares:
Renalytix Plc